Phase 2 trial of streptozotocin by continuous infusion for metastatic colorectal carcinoma.

Streptozotocin is a nitrosourea with minimal activity against colorectal carcinoma when given by bolus administration. Continuous infusion (CI) streptozotocin has been reportedly less toxic. Twenty-six patients with widely advanced colorectal carcinoma (most heavily pretreated) received 1-3 courses of Streptozotocin by CI to determine efficacy. Two patients (8%) had an objective response. Although CI Streptozotocin is less toxic, it does not have substantial efficacy in colorectal cancer in previously treated patients with widespread metastases.